case_images: PMC4510409_01
case_images: H & E stain of poorly differentiated prostate cancer. Representative image of high-grade prostate carcinoma from the cystoprostatectomy specimen exhibiting cribriform pattern and cell necrosis.
case_images: fonc-05-00169-g001.jpg
case_images: PMC4510409_01_fonc-05-00169-g001.jpg
case_images: F1
case_images: Pathology revealed high-grade prostatic adenocarcinoma with extensive sarcomatoid and focal neuroendocrine differentiation diffusely involving the prostate and extending into the seminal vesicles, urinary bladder wall including mucosa and large bowel wall, pT4N0 with 20 regional lymph nodes negative for malignancy (Figure 1).
case_images: Complete resolution of metastatic disease in response to cytotoxic therapy and veliparib. Computed tomography images showing pulmonary (top panel, arrow) and liver (bottom panel, arrow) metastases at baseline (A), after completion of cytotoxic therapy and veliparib (B), and after 38 cycles of veliparib maintenance therapy (C).
case_images: fonc-05-00169-g002.jpg
case_images: PMC4510409_01_fonc-05-00169-g002.jpg
case_images: F2
case_images: Imaging confirmed bowel wall thickening and showed other pelvic disease; progression of his lung metastases, largest measuring 3.5 cm; and new liver metastases, the largest 3.1 x 3.0 cm (Figure 2A). Repeat staging at the completion of six cycles showed continued decrease in size of lung metastases, stable liver metastases, and resolution of bowel wall thickening (Figure 2B). Ten months after completion of therapy, he had complete resolution of all sites of metastatic disease, and after 38 cycles of therapy continues to have no evidence of disease (Figure 2C).